Place of carbocysteine in the treatment of acute respiratory viral infections and bronchitis in therapeutic practice

In the structure of morbidity in the Russian Federation, respiratory system diseases are in the lead, among which acute respiratory viral infections and bronchitis are make up the majority, as well the leaders in the number of disability cases. The respiratory tract damage mechanisms in viral infections are diverse and require the use of a wide range of drugs. The pathology of the respiratory system in the vast majority of cases is accompanied by the development of cough as a key syndrome, reflecting the severity of the respiratory system, and the tension of the defense systems. When an infectious agent (usually a viral etiology) enters the respiratory system, several pathways for the formation of a pathological cough are triggered: inflammation products have a trigger effect on bronchial chemoreceptors, increasing the sensitivity of all cough receptors, causing expansion of mucosal microvessels, hypersecretion of glands. A violation of mucociliary clearance becomes inevitable along with changes in the volume and viscosity of sputum, which further aggravates the severity of cough and the patient's condition. The use of mucociliary transport stimulants is justified by their most important theirproperties. Carbocysteine, in addition to long-known effects (mucoregulatory, mucolytic, the ability to improve mucociliary transport), also has anti-inflammatory, immunomodulatory and antioxidant effects, which determines its importance in the acute respiratory viral infections and bronchitis treatment. Carbocisteine is recognized by the Russian Respiratory Society, the Scientific and Practical Council of the Ministry of Health of the Russian Federation, the National Medical Association of Otorhinolaryngologists, the Russian Union of Pediatricians as an effective active ingredient for the treatment of diseases of the upper and lower respiratory tract, which is reflected in the relevant modern recommendations of the Ministry of Health for the treatment of bronchitis in children, chronic bronchitis in adults, chronic obstructive pulmonary disease, acute sinusitis and acute otitis media in children and adults. The use of drugs with new pharmacological characteristics improves patient compliance.

1. On the state of sanitary and epidemiological well-being of the population in the Russian Federation in 2016: state report. Federal Service for Supervision of Consumer Rights Protection and Human Welfare. Moscow, 2017. 220 pp. (In Russ.)

2. Influenza. World Health Organization, 2018. Available at: https://www.who.int/ru/news-room/factsheets/detail/influenza-(seasonal) (date of access – 01.10.2021) (In Russ.)

3. Yushchuk N. D., Khadartsev O. S. Prevention of influenza and acute respiratory viral infections and their epidemic process characteristics // Infektsionnyye bolezni: novosti, mneniya, obucheniye. 2018; 2: 44-51 (In Russ.) DOI: 10.24411/2305-3496-2018-12004.

4. Kolbin A. S., Gomon Yu. M., Balykina Yu. E., et al. Socioeconomic and global burden of COVID-19. Kachestvennaya klinicheskaya praktika. 2021; 1: 24-34 (In Russ.). DOI: 10.37489/2588-0519-2021-1-24-34.

5. Kulagina M. G., Vertkin A. L., Zayratyants O. V., Nosova A. V. Key signs of infectious pathology, those proceeds with the defeat of the respiratory tract. // Infektsionnyye bolezni: novosti, mneniya, obucheniye. 2021; Т. 10. № 1 (36); 79-88. (In Russ.)

6. Vertkin A. L., Dudina K. R., Nosova A. V. Portrait of a patient with an infectious pathology // Infektsionnyye bolezni: novosti, mneniya, obucheniye. 2020; Т. 9. № 2 (33): 120-123. (In Russ.)

7. Klyachkina I. L., Rybachenko V. V., Knorring G. Yu., Voronina E. V. Experience and prospects of systemic enzyme therapy in the treatment of respiratory diseases // Doktor.Ru. 2006; 2: 31-35. (In Russ.)

8. Vertkin A. L., Prokhorovich E. A., Namazova L. S., et al. Optimization of empiric therapy for community-acquired pneumonia in elderly and senile patients // Russkiy meditsinskiy zhurnal. 2002; 16: 708-712. (In Russ.)

9. Zaitsev A. А. Cough: Problems and Solutions // Prakticheskaya pulmonologiya. 2020; (2): 78-86. (In Russ.)

10. Ryabova V. A. Relevance of the use of mucoactive drugs for coughing with different etiopathogenesis during the COVID-19 pandemic // Effectivnaya farmakoterapiya. 2020; 16 (34): 20-25. (In Russ.) DOI: 10.33978/2307-35862020-16-34-20-25.

11. [Kazantsev V. A. Mucoactive therapy in the treatment of patients with lower respiratory tract infections // Meditsinskii sovet. 2015; 16: 83-89. (In Russ.)

12. [Klyachkina I. L., Smirnov I. P. Algorithm of choice of drugs for the treatment of cough // Farmateka. 2017; 14 (347): 28-33. (In Russ.)

13. Berezhnoi V. V., Glyadelova N. P. Mukoregulative preparations in the treatment of cough due to the respiratory tract diseases in children (literature review) // Sovremennaya pediatriya. 2015. 8 (72): 57-66. (In Russ.).

14. Klyachkina I. L., Belotserkovskaya Yu. G., Romanovskikh A. G. Mucoregulators in the treatment of acute respiratory viral infection // RMJ. 2018; 3 (1): 14-18. (In Russ.)

15. Duijvestijn Y. C., Mourdi N., Smucny J., et al. Acetylcysteine and carbocysteine for acute upper and lower respiratory tract infections in paediatric patients without chronic broncho-pulmonary disease // Cochrane Database Syst Rev. 2009; Vol. 21 (1), CD003124.

16. Sinopalnikov A. I., Klyachkina I. L. Cough. Moscow: Medical Information Agency, 2013. (In Russ.)

17. Okovity S. V., Zaitsev A. A., Anisimova N. A. Pharmacodynamic approaches to the use of mucoactive drugs // Lechaschi Vrach. 2020; 10: 6-10. (In Russ.)

18. Babak S. L., Gorbunova M. V., Malyavin A. G. Mucins and carbocisteine: respiratory protection // Terapiya. 2021; 8: 160-168. (In Russ.) DOI: 10.18565/therapy.2021.10.160-168.

19. Mizernitsky Yu. L., Melnikova I. M. The place of carbocysteine in outpatient pediatric practice // Lechaschi Vrach. 2018; 9: 42-45. (In Russ.)

20. Havez R., Degand P., Roussel P., et al. Biochemical mechanism of action of cysteine derivatives on bronchial mucus // Poulmon Coeur. 1970; 26: 81-90.

21. Maccio A., Madeddu C., Panzone F., et al. Carbocysteine: clinical experience and new perspectives in the treatment of chronic inflammatory diseases // Expert Opin Pharmacother. 2009; 10: 693-703. DOI: 10.1517/14656560902758343.

22. Ryazantsev S. V. The role of Fluditec (Carbocisten) in mucolytic therapy of the upper respiratory tract and ear // Ros. J. otorhinolar. 2005; 1 (14): 117-119. (In Russ.)

23. Chang A. B., Widdicombe J. G. Cough throughout life: children, adults and the senile // Pulm Pharmacol Ther. 2007; Vol. 20: 371-382.

24. Nogawa H., Ishibashi Y., Ogawa A., Masuda K., Tsubuki T., Kameda T., et al. Carbocisteine can scavenge reactive oxygen species in vitro // Respirology. 2009; 14: 53-59.

25. Wang W., Guan W., Huang R.-Q., Xie Y.-Q., et al. Carbocisteine attenuates TNF-α-induced inflammation in human alveolar epithelial cells in vitro through suppressing NF-κB and ERK1/2 MAPK signaling pathways // Acta Pharmacol Sin. 2016; 37 (5): 629-636. DOI: 10.1038/aps.2015.150.

26. Shuganov E. G., Salmasi Zh. M., Shuganov A. E. Clinical and immunological effects of carbocysteine in chronic obstructive pulmonary disease // Almanakh klinicheskoi meditsiny. 2014; 35: 66-70. (In Russ.)

27. Pace E., Ferraro M., Di Vincenzo S., Cipollina C., et al. Comparative cytoprotective effects of carbocysteine and fluticasone propionate in cigarette smoke extract-stimulated bronchial epithelial cells // Cell Stress Chaperones. 2013; 18 (6): 733-743. DOI: 10.1007/s12192-013-0424-0.

28. Malhotra D., Thimmulappa R. K., Mercado N., et al. Denitrosylation of HDAC2 by targeting Nrf2 restores glucocorticosteroid sensitivity in macrophages from COPD patients // J Clin Invest. 2011; 121: 4289-4302. DOI: 10.1172/JCI45144.

29. Yasuda H., Yamaya M., Sazaki T., et al. Carbocysteine inhibits rhinovirus infection in human tracheal epithelial cells // Eur. Respir. J. 2006; 28: 51-58.

30. Yamaya M., Nishimura H., Shinya K. Inhibitory effects of carbocisteine on type A seasonal influenza virus infection in human airway epithelial cells // Am. J. Physiol. Lung. Cell. Mol. Physiol. 2010; Vol. 299 (2): 160-168.

31. Asada M., Yoshida M., Hatachi Y. Сarbocisteine inhibits respiratory syncytial virus infection in human tracheal epithelial cells // Respiratory Physiology and Neurobiology. 2012; Vol. 180 (1): 112-118.

32. Sumitomo T., Nakata M., Yamaguchi M., et al. Сarboxymethylcysteine inhibits adherence of Streptococcus pneumoniae to human alveolar epithelial cells // Journal of Medical Microbiology. 2012; Vol. 61: 101-108.

33. Suer E., Sayrac S., Sarinay E., et al. Variation in attachment of Streptococcus pneumoniae to human pharyngeal epithelial cells after treatment with S+carboxymethylcysteine // J Infect Chemother. 2008; Vol. 14: 333-336.

34. Instructions for use of the medicinal product for medical use Fluditec (INN Carbocysteine).

35. Chezzi G. L., Zanocco P., Arrigoni G. Valutazione control-lata di un mucoregolatore, la carbocisteina, in un gruppo di pazzi-enti affetti da rinopatie chroniche catarrali. La Carbocisteina Oggi. Septembre, 1987.

36. Catalano G. B., Mallanino N., Serra A. La carbocisteina nella patologia flogistica cronica rinosinusale // Otorinolaringologia. 1981; 31: 1-11.

37. Kumasava Т., Ushiro K. Clinical evaluatin of SCMC syrup applied in the treatmeht, lof otitis media with effusion // Acta Otolaringol (Stockh). 1988; (suppl. 458): 56-62.

38. Spingo G., Teatini G. P. Valutazione dell 'efficacia della carbocisteina nel trattamentodelle otiti catarrali // Oto. Rino. Laring. 1981; 31: 1-4.

39. Spingo G., Teatini G. P. L 'impiego di un mucolitico orale nel trattamento dell otiti sieromucose // Nuevo Arch. Ital. 1977; 5: 115-122.

40. Majima Y., Kurono Y., Hirakawa K., et al. Efficacy of combined treatment with S-carboxymethylcysteine (carbocisteine) and clarithromycin in chronic rhinosinusitis patients without nasal polyp or with small nasal polyp // Auris Nasus Larynx. 2012; 39 (1): 38-47.

41. Овчинников А. Ю., Панякина М. А. Positive experience of complex conservative treatment of acute and chronic sinusitis in the acute stage. effective pharmacotherapy // Pulmonologiya I otorhinolaringologiya. 2010; 2: 84-90. (In Russ.)

42. Tarasova G. D. Effect of Fluditec on inflammation of the nasal cavity // Ros. Rinologiya. 2005; 2: 201. (In Russ.)

43. Tarasova G. D., Ivanova T. V., Protasov P. G. Fluditec in the treatment of inflammatory diseases of the upper respiratory tract // Rossiiskaya otorinolaringologiya. 2005; 6 (19): 77-81. (In Russ.)

44. Balyasinskaya G. L., Lyumanova S. R., Landa R. I. Significance of mucoactive therapy in the treatment of acute sinusitis in children // Rossiiskaya otorinolaringologiya. 2006; 6 (25): 84-86. (In Russ.)

45. Allegra L., Cordaro C. I., Grassi C. Prevention of acute exacerbations of chronic obstructive bronchitis with carbocysteine lysine salt monohydrate: a multicenter, double-blind, placebo-controlled trial // Respiration. 1996; 63: 174-180.

46. Tatsumi K., Fukuchi Y. Carbocysteine improves quality of life in patients with chronic obstructive pulmonary disease // J. Am. Geriatr. Soc. 2007; 55: 1884-1886.

47. Yasuda H., Yamaya M., Sasaki T., et al. Carbocysteine reduces frequency of common colds and exacerbations in patients with chronic obstructive pulmonary disease // J. Am. Geriatr. Soc. 2006; 54: 378-380.

48. Zheng J. P., Kang J., Huang S. G., et al. Effect of carbocysteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomized placebo-controlled study // Lancet. 2008; 371: 2013-2018.